Evidence map›Paper›PMID 42781024›Full record

ArticleNeuro-oncology advances

Diagnosis and treatment decision of an IDH-mutant glioma through CSF-based cfDNA sequencing.

Eve Fouarge, Rouzbeh Banan, Sebastian Curt Schulz, Martin Jakobs, Marianne Schell, Felix Sahm, Tobias Kessler

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eve FouargeNeurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Rouzbeh BananDepartment of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.
Sebastian Curt SchulzNeurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Martin JakobsDepartment of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany.
Marianne SchellDepartment of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-9754-1350
Felix SahmDepartment of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.ORCID https://orcid.org/0000-0001-5441-1962
Tobias KesslerNeurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.ORCID https://orcid.org/0000-0001-8350-7074

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Classification of tumors of the central nervous system currently requires tumor tissue analysis for histology and molecular markers, according to the 2021 WHO Classification of Tumors of the Central Nervous System. Cerebrospinal fluid (CSF)-based cell-free DNA (cfDNA) sequencing detects these defining molecular alterations and allows for accurate diagnosis and WHO-analogue tumor classification. We hereby report the case of a female patient with an IDH-mutant glioma, TERT promoter mutant, NEC, in whom

Indexed as

cfDNA sequencingCSFIDH mutant gliomaliquid biopsy

Identifiers

PMID42781024
PMCPMC13599777

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.